Introduction
Results
Patients’ characteristics
Variable | A-LMR ≥ 1 (N = 59) | A-LMR < 1 (N = 50) |
p value |
---|---|---|---|
At diagnosis | |||
Age, years, median (range) | 53 (18–71) | 56 (20–75) | 0.2 |
Gender | 0.2 | ||
Male | 38 (64 %) | 25 (50 %) | |
Female | 21 (36 %) | 25 (50 %) | |
LDH (U/L), median (range) | 211 (116–928) | 276.5 (137–1539) | 0.04 |
Extra-nodal site | 0.05 | ||
0 | 7 (12 %) | 6 (12 %) | |
1 | 49 (83 %) | 34 (68 %) | |
2 | 3 (5 %) | 10 (20 %) | |
B symptoms | 0.9 | ||
Yes | 17 (29 %) | 15 (30 %) | |
No | 42 (71 %) | 35 (70 %) | |
Stage | <0.001 | ||
I | 2 (3 %) | 1 (2 %) | |
II | 26 (44 %) | 5 (10 %) | |
III | 9 (15 %) | 12 (24 %) | |
IV | 22 (38 %) | 32 (64 %) | |
Bone marrow involvement | 0.5 | ||
Yes | 15 (25 %) | 16 (32 %) | |
No | 44 (75 %) | 34 (68 %) | |
Bulky disease | 0.8 | ||
Yes | 3 (5 %) | 6 (6 %) | |
No | 56 (95 %) | 47 (94 %) | |
Hemoglobin (g/dl), median (range) | 12.5 (8.1–13.1) | 12.5 (6.6–16.9) | 0.6 |
Platelets × 109/l, median (range) | 231 (14–626) | 214 (31–719) | 0.06 |
IPI score | 0.01 | ||
0 | 13 (22 %) | 2 (4 %) | |
1 | 19 (32 %) | 12 (24 %) | |
2 | 17 (29 %) | 18 (36 %) | |
3 | 8 (13 %) | 10 (20 %) | |
4 | 1 (2 %) | 7 (14 %) | |
5 | 1 (2 %) | 1 (2 %) | |
Performance status | 0.3 | ||
0 | 7 (12 %) | 4 (8 %) | |
1 | 45 (76 %) | 43 (86 %) | |
2 | 5 (8 %) | 3 (6 %) | |
3 | 2 (45 %) | 0 (0 %) | |
T-cell lymphoma histologies | 0.9 | ||
Anaplastic large cell | 10 (17 %) | 5 (13 %) | |
Angioimmunoblastic | 15 (25 %) | 15 (27 %) | |
Enteropathy-associated | 6 (10 %) | 3 (6 %) | |
Hepatosplenic | 1 (2 %) | 1 (2 %) | |
NK/T | 7 (12 %) | 6 (12 %) | |
Panniculitis | 4 (7 %) | 3 (6 %) | |
Peripheral | 16 (27 %) | 17 (34 %) | |
IPI factors | |||
Age, years | 0.3 | ||
60 | 18 (31 %) | 20 (40 %) | |
≤60 | 41 (69 %) | 30 (60 %) | |
LDH (U/L) | 0.03 | ||
Normal | 34 (58 %) | 18 (36 %) | |
Abnormal | 25 (42 %) | 32 (64 %) | |
Performance status | 0.3 | ||
1 | 7 (12 %) | 3 (6 %) | |
≤1 | 52 (88 %) | 47 (94 %) | |
Extra-nodal disease | 0.02 | ||
1 | 3 (5 %) | 10 (20 %) | |
≤1 | 56 (95 %) | 40 (80 %) | |
Stage | <0.001 | ||
I/II | 28 (47 %) | 6 (12 %) | |
III/IV | 31 (53 %) | 44 (88 %) | |
IPI index | 0.03 | ||
2 | 10 (17 %) | 18 (36 %) | |
≤2 | 49 (83 %) | 32 (64 %) | |
Initial chemotherapy | 0.9 | ||
CHOP | 58 (98 %) | 49 (98 %) | |
SMILE | 1 (2 %) | 1 (2 %) | |
Salvage chemotherapy (N = 51) | 0.2 | ||
CDE | 2 (9 %) | 0 (0 %) | |
DHAP | 5 (21 %) | 8 (29 %) | |
ICE | 16 (70 %) | 20 (71 %) | |
Up-front transplant | 0.09 | ||
Yes | 36 (61 %) | 22 (44 %) | |
No | 23 (39 %) | 28 (56 %) | |
At transplant | |||
Pre-transplant clinical status | <0.001 | ||
CR | 51 (86 %) | 25 (50 %) | |
PR | 8 (15 %) | 25 (50 %) | |
Plerixafor | 0.8 | ||
Yes | 21 (36 %) | 19 (38 %) | |
No | 38 (64 %) | 31 (62 %) | |
Infused CD34, median (range) | 5.42 (2.25–13.44) | 5.12 (2.04–15.65) | 0.9 |
Number of collections | 0.08 | ||
1 | 7 (12 %) | 12 (24 %) | |
2 | 19 (32 %) | 15 (30 %) | |
3 | 19 (32 %) | 9 (18 %) | |
4 | 7 (12 %) | 11 (22 %) | |
5 | 1 (2 %) | 2 (4 %) | |
6 | 3 (5 %) | 0 (0 %) | |
7 | 2 (3 %) | 0 (0 %) | |
8 | 1 (2 %) | 1 (2 %) | |
A-ALC, median (range) | 0.68 (0.21–3.83) | 0.44 (0.06–1.40) | <0.001 |
A-AMC, median (range) | 0.45 (0.10–1.42) | 0.78 (0.20–1.60) | <0.001 |
ALC-15, median (range) | 0.71 (0.10–2.31) | 0.41 (0.10–1.18) | <0.001 |
AMC-15, median (range) | 0.43 (0.04–1.19) | 0.90 (0.20–2.31) | <0.001 |
LMR-15 | 1.71 (0.24–15.5) | 0.57 (0.08–3.18) | <0.001 |
Cut-off values for A-ALC, A-AMC, A-LMR, ALC-15, AMC-15, and LMR-15 for survival analysis
Correlation between A-ALC and ALC-15, A-AMC and AMC-15, and A-LMR and LMR-15
Predictors for OS and PFS
Variable | OS | PFS | ||||
---|---|---|---|---|---|---|
HR | 95 % CI |
p
| HR | 95 % CI |
p
| |
Age > 60 years | 1.532 | 0.784–2.900 | 0.2 | 1.400 | 0.789–2.422 | 0.2 |
Female versus male | 1.153 | 0.606–2.170 | 0.7 | 1.359 | 0.787–2.342 | 0.3 |
B symptoms | 1.919 | 1.094–3.615 | 0.05 | 1.425 | 0.790–2.485 | 0.2 |
Bulky disease | 1.007 | 0.164–3.294 | 0.9 | 1.109 | 0.270–3.024 | 0.9 |
Hemoglobin < 12.0 g/dl | 1.636 | 0.862–3.072 | 0.1 | 1.858 | 1.076–3.193 | 0.03 |
Platelet < 150 × 109/l | 2.566 | 1.312–4.862 | 0.007 | 2.890 | 1.671–5.047 | <0.001 |
Extra-nodal sites > 1 | 3.043 | 1.354–6.197 | 0.009 | 2.332 | 1.104–4.470 | 0.03 |
LDH (U/L) | 6.695 | 3.001–17.77 | <0.001 | 4.510 | 2.440–8.989 | <0.001 |
Performance status > 1 | 1.788 | 0.674–3.972 | 0.2 | 2.033 | 0.885–4.089 | 0.09 |
Stage III/IV | 3.817 | 1.630–11.160 | <0.001 | 2.571 | 1.393–5.431 | 0.004 |
IPI > 2 | 4.442 | 2.342–8.459 | <0.001 | 3.734 | 2.146–6.444 | <0.001 |
Positive bone marrow | 1.670 | 0.856–3.153 | 0.1 | 1.294 | 0.709–2.271 | 0.4 |
Infused CD34 | 0.893 | 0.758–1.032 | 0.1 | 0.950 | 0.832–1.070 | 0.4 |
CR prior to APHSCT | 0.164 | 0.081–0.314 | <0.001 | 0.186 | 0.106–0.321 | <0.001 |
A-ALC ≥ 0.5 × 109/kg | 0.358 | 0.188–0.676 | 0.002 | 0.294 | 0.167–0.511 | <0.001 |
A-AMC ≥ 0.6 × 109/kg | 3.207 | 1.585–7.175 | <0.001 | 2.254 | 1.285–4.116 | 0.004 |
A-LMR ≥ 1 | 0.155 | 0.066–0.322 | <0.001 | 0.196 | 0.104–0.353 | <0.001 |
ALC-15 ≥ 0.5 cells/μl | 0.158 | 0.072–0.304 | <0.001 | 0.246 | 0.139–0.430 | <0.001 |
AMC-15 ≥ 0.5 cells/μl | 3.909 | 1.881–9.160 | <0.001 | 2.645 | 1.489–4.918 | <0.001 |
LMR-15 | 0.143 | 0.061–0.497 | <0.001 | 0.214 | 0.116–0.378 | <0.001 |
Plerixafor | 0.954 | 0.497–1.925 | 0.7 | 0.886 | 0.510–1.587 | 0.8 |
Variable | OS | PFS | ||||
---|---|---|---|---|---|---|
HR | 95 % CI |
p
| HR | 95 % CI |
p
| |
A-ALC ≥ 0.5 × 109/kg | 0.401 | 0.231–0.972 | 0.04 | 0.439 | 0.271–0.902 | 0.03 |
A-AMC < 0.6 × 109/kg | 0.502 | 0.100–0.985 | 0.04 | 0.490 | 0.288–0.911 | 0.03 |
A-LMR ≥ 1 | 0.258 | 0.105–0.561 | <0.001 | 0.298 | 0.112–0.482 | <0.001 |
CR prior to APHSCT | 0.356 | 0.166–0.731 | 0.005 | 0.401 | 0.211–0.681 | 0.008 |
Hemoglobin < 12 g/dl | 1.592 | 0.861–2.935 | 0.1 | |||
IPI > 2 | 2.377 | 1.163–4.972 | 0.02 | 1.398 | 0.705–2.771 | 0.3 |
Platelet < 150 × 109/l | 1.297 | 0.627–2.607 | 0.5 | 1.164 | 0.590–2.268 | 0.7 |